|Bid||176.34 x 800|
|Ask||177.85 x 1000|
|Day's Range||174.87 - 177.57|
|52 Week Range||165.22 - 210.19|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||13.97|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||5.80 (3.05%)|
|1y Target Est||207.38|
When Pfizer (NYSE:PFE) won its first approval for cancer drug Ibrance back in February 2015, as a treatment for ER+/HER2- breast cancer, investors were cautiously optimistic. PFE stock holders knew it worked well enough for a narrow subset of breast cancer patients, but expectations for the then-nascent therapy were clearly high.Source: Maciek Lulko (Modified)The drug hasn't disappointed. Since early 2015, Ibrance has been approved for three more indications, with the most recent one taking shape just this month. As it turns out, the treatment has proven effective as a therapy for some of the rare cases where men develop breast cancer.It's a testament to the drug's incredible versatility and efficacy.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd yet, while Ibrance is still in trials looking for even more approved uses, the company's future hardly hinges on what's quickly turning into a blockbuster drug. The market is largely overlooking much of Pfizer's pipeline. Catalysts AheadBank of America Merrill Lynch analyst Jason Gerberry made the point of making the call three weeks ago, upping the brokerage firm's price target on PFE stock from $45 to $48 on upcoming catalysts related to the development of two orphan drugs.Orphan drugs, in short, take aim at underserved areas of the pharmaceutical market. In many cases there are so few cases of a particular illness that no pharmaceutical company bothers developing an option, so when one does, the FDA facilitates an easier path to approval; something is better than nothing.One such drug in Pfizer's pipeline is Vyndaqel.It's not a new drug. In fact, it was first approved back in 2011. Its potential use as a treatment for cardiomyopathy, however, is in the works, and is expected to launch later this year to a receptive caregiver environment.All told, BofA-ML's Gerberry sees peak sales of $2 billion for Vyndaqel.Gerberry also notes that a Pfizer gene therapy candidate -- PF-06939926 for Duchenne muscular dystrophy -- is closer to the endzone than many current and would-be owners of PFE stock may realize. Though in Phase 1 testing right now, should the R&D update slated for the middle of the year go as well as expected, the drugmaker may be able to leap straight to Phase 3 trials and catch up with a similar development from DMD rival Sarepta Therapeutics (NASDAQ:SRPT). * 7 High-Risk Stocks With Big Potential Rewards Again, it's not only another catalyst that could draw a bullish crowd, but it's also a development that could put real revenue growth on the table real soon. The Duchenne muscular dystrophy market could be worth more than $4 billion by 2023.Outside of Gerberry's discussion, Pfizer's Vizimpro was approved earlier this month in Europe as a first-line treatment of locally advanced or metastatic non-small cell lung cancer.Pfizer's still got its R&D, or at least its therapy-acquiring, chops. Heavy HittersThough PF-06939926 and Vyndaqel should prove to be solid bolt-on revenue and profit centers, there's still little doubt that Ibrance will be the company's heavy hitter -- and growth driver -- for the foreseeable future.As of the company's most recent quarterly report, 12-month revenue for the wonder drug reached $4.1 billion, up 32% from the trailing-12-month figure reported a year earlier. New approvals and expanded usage for previously approved indications both helped.The drug, though, has still only scratched the surface. Some analysts are calling for peak revenue of around $8 billion before Ibrance runs out of room to grow and is crimped by rival drugs.Again, that potential is a testament to the drug's flexibility.Ibrance isn't the only heavy-hitter still in growth mode in Pfizer's lineup though. While Enbrel (sold by Pfizer in Europe), Sutent and Celebrex may all be major names with declining revenue, sales of fibromyalgia treatment Lyrica appear to have stabilized around an annual pace of $4.6 billion. Ditto for pneumococcal bacteria treatment Prevnar, which has driven more than $5 billion in sales over the course of the past four reported quarters.In the meantime, Pfizer has started to shine in an area that had quietly gnawed at PFE stock owners… biosimilars. The company has sold $642 million worth of ulcerative colitis, arthritis and plaque psoriasis drug Inflectra/Remsima over the past year, up 50% year-over-year, and suggesting it doesn't have to yield to the pharmaceutical industry's biosimilar powerhouses like Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN). * 7 Stocks to Buy for Spring Season Growth Pfizer's got five biosimilar drugs in the works, positioning it for deeper penetration of an admittedly-crowded market forecasted to be worth more than a stunning $60 billion by 2024. Bottom Line for PFE StockPFE stock is down 15% from its November peak, never really rebounding with the rest of the market beginning in January. Shares are down 10% just since early April, as the future of U.S. health care has become blurred by political rhetoric. Indeed, Pfizer stock hasn't made net progress since the middle of last year. Clearly there's something wrong with the company.Or, maybe there isn't.Though the headlines and sentiment seem dire, that pessimism is largely rooted in investors' collective view that sees a glass as half-empty rather than half-full. Pfizer's got a quietly potent pipeline, though, with a mix of already-approved and new drugs closer to wrapping up clinical trials than many investors might realize.That may not be enough to stave off headline-driven headwinds in the short run. But, there's a reason a streak of downgrades late last year has been countered this year with a couple of upgrades to an "Outperform'" rating.One of those upgrades came from Credit Suisse, with analyst Vamil Divan noting that patent woes working against aforementioned therapies like Enbrel and Celebrex are starting to abate at the same time new therapies are reaching their full stride.It's just a story not many investors are paying attention to right now.As of this writing, James Brumley did not hold a position in any of the aforementioned companies. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post Pfizer Stock Suffers From an Underappreciated Drugs Pipeline appeared first on InvestorPlace.
The healthcare sector has been absolutely crushed lately. This negative momentum appears to have been driven by a recent uptick in political rhetoric regarding healthcare reform. It's rare to find an issue in Washington D.C. that has bi-partisan support, but healthcare reform seems to fit that bill.
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Yesterday's strong start didn't end up with a strong finish, though it wasn't disastrous either. The S&P 500 ended up closing at 2,900.45, down 0.23%. Higher volume and a "bottomy" VIX suggests this could be a major pivot point, though it's far too soon to make such a call yet.Source: Allan Ajifo via Wikimedia (Modified)The indices may have fared considerably better had it not been for Sprint (NYSE:S). Shares of the wireless company slumped more than 6% on whispers that its intended merger with T-Mobile (NASDAQ:TMUS) may meet resistance with the Department of Justice.At the other end of the spectrum, Qualcomm (NASDAQ:QCOM) jumped 12% after it and Apple (NASDAQ:AAPL) finally (mostly) ended a long-standing legal battle over intellectual property.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNone of those names are especially great trading prospects as we kick off the last trading day of the holiday-shortened weak. Rather, it's the stock charts of Goldman Sachs Group (NYSE:GS), Amgen (NASDAQ:AMGN) and Citrix Systems (NASDAQ:CTXS) that merit the closest looks. Amgen (AMGN)AMGN stock isn't beyond salvaging yet. But, it's taking on water. A little more downside could do the trick and put a self-sustaining selloff into motion. Click to Enlarge * The technical problem is most evident on the weekly chart. The lower boundary of the rising trading channel hasn't cleanly kept the uptrend intact. In fact, Wednesday's close was below that floor. * There are still two horizontal floors in place, both plotted in red on both stock charts. Each is a level at which AMGN stock has made key lows since October. * It's subtle, but the string of lower highs seen since the early December peak is the first time we've seen two lower lows since 2015. Citrix Systems (CTXS)Citrix Systems is a name that has been on our radar, and examined frequently, for the better part of the past few months. With our last look on April 4, a failed effort to break above a major ceiling was a major red flag that the bulls just aren't ready to roll.Since then, things have continued to deteriorate. CTXS stock remains below a minor support level, and a couple of major support lines are under attack. Click to Enlarge * One of those support lines is right around $98, plotted in green on the daily chart. That's where Citrix stock bottomed a couple of times since October. * Zooming out to the weekly chart, we can see the support line -- plotted in blue -- that has tagged both major lows since early 2016 is also under pressure. * The lower edge of the converging wedge pattern marked by yellow lines on both stock charts hasn't been able to keep CTXS stock propped up since March. Goldman Sachs Group (GS)GS stock hasn't made any major net progress since January's surge. But, it has been working on a breakout thrust that's almost ready to launch. One or two more good days could do the trick, and the backdrop is already as encouraging as it needs to be. Click to Enlarge * The make-or-break level in question is right around $208, where the white 200-day moving average line currently lies, and where the resistance line that tags the prior three major highs also awaits. That line is plotted in yellow on both stock charts. * Zooming out to the weekly timeframe we can see the past four slightly bullish weeks have been on decent -- and growing -- volume.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for Spring Season Growth * This Is How You Beat Back a Bear Market * 7 Dental Stocks to Buy That Will Make You Smile Compare Brokers The post 3 Big Stock Charts for Thursday: Citrix Systems, Goldman Sachs Group and Amgen appeared first on InvestorPlace.
Long-Established Science Education Program to Give Local Secondary School Students Hands-On Biotechnology Lab Experience TAMPA, Fla. , April 17, 2019 /PRNewswire/ -- The Amgen Foundation, together with ...
Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.
At first glance, shares of Amgen (NASDAQ:AMGN) look quite volatile. Upon further inspection, though, the six-month range in AMGN stock is actually pretty tight -- and it's been getting even tighter, as the stock has spent much of 2019 gathering in tightening coil. This sets up for a potentially large move. This move can happen in either direction, with bulls hoping Amgen stock resolves higher. * 7 Stocks That Can Outperform for Years Source: Richard Masoner via Flickr There are a lot of considerations when it comes to pulling the trigger on a name like Amgen. It's not just the technicals, but also the dividend, its valuation and growth profile. Let's take a closer look, first with the charts. Trading AMGN Stock Click to EnlargeAMGN is not the kind of stock that traders are normally drawn to. That's more for the names like Advanced Micro Devices (NADSAQ:AMD), Tesla (NASDAQ:TSLA) and others. But that doesn't mean we can't trace the technicals on AMGN stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAt the end of March, AMGN stock was showing weakness and threatening to break down from a short-term double-top. Fast-forward about two weeks and Amgen stock is above all of its major moving averages. While being rejected by downtrend resistance (black line), shares are hanging just below this mark. Could that set up a breakout?That's what I'm looking for in AMGN stock. A drop down to about $190 would give bulls a chance to initiate a position near the 20-day moving average and uptrend support. Whether the pullback is done here, near $193, or drops to $190, as long as support holds, it could give AMGN stock the energy it needs to push through resistance.On the upside, a push through $196 could eventually ignite Amgen up to $206. Shares put in a double-top at this level in the fourth quarter, so it wouldn't be surprising to see this area act as resistance on AMGN's first try. On the downside, watch for support from the 50-day moving average at $188 -- provided uptrend support does not buoy Amgen.Below that, and a drop into the low-$180s is possible. Valuing Amgen StockAmgen stock is looking better and better on the charts, but that doesn't mean there aren't things to like about its fundamentals.For starters, AMGN stock has a 3% dividend yield. Management gave a ~10% bump in December, following increases of ~15% in each of the last two years ago. While the company has experienced lower growth than the past few years, it's clear management is putting an emphasis on returning capital to investors.There's also the valuation, which stands at less than 14 times this year's earnings. There is a catch, though: While this is a below-market valuation, we have to consider it versus its peers as well as against Amgen's own growth profile. When compared to names like Celgene (NASDAQ:CELG), Bristol-Myers Squibb (NYSE:BMY) (who are in M&A discussions) and Gilead (NASDAQ:GILD), Amgen stock is expensive.These stocks trade at roughly 10 times earnings or less, so, at 13.7 times this year's earnings, Amgen looks less attractive. It would help if it had better growth, too. Analysts expect revenue to decline almost 4% this year and for earnings to fall about 2% year over year. That said, consensus expectations do call for a rebound in both metrics in 2020 while AMGN could always top expectations this year. After all, it has beat -- rather impressively, I might add -- top- and bottom-line expectations in each of the past four quarters. * 10 Stocks That Are Screaming Buys Right Now One last note, AMGN stock is actually trading at a discount compared to its five-year average valuation -- and that's not just the price-to-earnings ratio either. Amgen isn't perfect, but if shares are going to break out this year, I don't expect the valuation to inhibit that move.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post Why Amgen Stock Could Break Out to New Highs appeared first on InvestorPlace.
Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. The U.S. Food and Drug Administration last week approved bone-building Evenity for postmenopausal women who are at high risk of fracture, but required the label to have a boxed warning, the FDA’s strictest, flagging increased risk of heart attack, stroke and cardiovascular-related death. Since the drug's target population of older women has underlying risk for such cardiovascular problems, Wall Street analysts have pulled back on sales expectations for Evenity, which was developed jointly with Belgium-based UCB SA.
THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture. "Osteoporosis is a silent disease that can lead to devastating consequences. Unfortunately, only 20 percent of women who have experienced a fracture receive any type of osteoporosis treatment post-fracture," said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen.
Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...
Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
Amgen announced late Tuesday the FDA approved Evenity, chemically romosozumab-aqqg, for treating osteoporosis in postmenopausal women at high risk of breaking a bone. Evenity is a monoclonal antibody that blocks the effects of the protein sclerostin and works by increasing new bone formation. The large-cap biotech said it is the first and only bone-builder with a unique dual effect of increasing bone formation and to a lesser extent reducing bone loss, thereby rapidly reducing the risk of fracture.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 9) Edap Tms SA (NASDAQ: EDAP ) INmune Bio Inc (NASDAQ: ...
Postmenopausal osteoporosis is a chronic condition resulting from progressive bone loss beginning around menopause. The monthly injection, Evenity, developed jointly with Belgium-based UCB SA, helps reduce the risk of fracture by increasing bone mass and mildly inhibiting the break down of bone minerals. Evenity comes with a boxed warning, the FDA's strictest warning, flagging increased risk of heart attack, stroke and cardiovascular-related death.